Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study.

Ther Adv Med Oncol · 2026 · PMC13291449 · PMID 42359362

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significancep = 0.063so close (0.05 < p ≤ 0.1)

This difference did not reach statistical significance (Fisher’s exact test, p = 0.063).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.